FDA has partnered with U.S. Customs and Border Protection (CBP) to expand the focus of the Global Business Identifier (GBI) Test, which is examining how identifiers—unique numbers that capture information about legal business entities and their functions—can be leveraged to address a range of supply chain traceability needs.